Analyst Activity – Wedbush Raises Its Price Target On NASDAQ:STML – Stemline Therapeutics (NASDAQ:STML) to

Analyst Ratings For NASDAQ:STML – Stemline Therapeutics (NASDAQ:STML)

Today, Wedbush raised its price target on NASDAQ:STML – Stemline Therapeutics (NASDAQ:STML) to per share.

Some recent analyst ratings include

  • 5/10/2018-Cowen Reiterated Rating of Buy.
  • 5/25/2017-Jefferies Group Reiterated Rating of Buy.
  • 12/7/2016-Roth Capital Reiterated Rating of Buy.

Recent Insider Trading Activity For NASDAQ:STML – Stemline Therapeutics (NASDAQ:STML)
NASDAQ:STML – Stemline Therapeutics (NASDAQ:STML) has insider ownership of 15.70% and institutional ownership of 64.40%.

  • On 3/13/2018 Kenneth Hoberman, COO, sold 29,987 with an average share price of $17.14 per share and the total transaction amounting to $513,977.18.
  • On 3/12/2018 David Gionco, Insider, sold 9,183 with an average share price of $17.38 per share and the total transaction amounting to $159,600.54.
  • On 3/12/2018 Ivan Bergstein, CEO, sold 37,857 with an average share price of $17.34 per share and the total transaction amounting to $656,440.38.
  • On 3/7/2018 David Gionco, Insider, sold 1,413 with an average share price of $16.56 per share and the total transaction amounting to $23,399.28.
  • On 3/7/2018 Ivan Bergstein, CEO, sold 6,797 with an average share price of $16.56 per share and the total transaction amounting to $112,558.32.
  • On 3/7/2018 Kenneth Hoberman, COO, sold 3,027 with an average share price of $16.55 per share and the total transaction amounting to $50,096.85.
  • On 2/27/2018 David Gionco, Insider, sold 8,984 with an average share price of $17.43 per share and the total transaction amounting to $156,591.12.

Recent Trading Activity for NASDAQ:STML – Stemline Therapeutics (NASDAQ:STML)
Shares of NASDAQ:STML – Stemline Therapeutics closed the previous trading session at 19.45 up +0.30 1.57% with 106439 shares trading hands.

An ad to help with our costs